STOCK TITAN

DiaMedica Therapeutics (DMAC) Stock News

DMAC NASDAQ

DiaMedica Therapeutics Inc. develops clinical-stage biopharmaceutical programs for serious ischemic diseases, with a focus on preeclampsia, fetal growth restriction and acute ischemic stroke. Its lead candidate, DM199, is a recombinant synthetic form of the KLK1 protein being studied in maternal-fetal and stroke indications.

Company news commonly covers DM199 clinical and regulatory updates, including preeclampsia studies, the ReMEDy2 Phase 2/3 acute ischemic stroke trial, Health Canada clearances and FDA pre-IND interactions. Updates also include financial results, cash runway commentary, equity financing activity, investor conference participation and equity compensation actions under Nasdaq rules.

Rhea-AI Summary

DiaMedica Therapeutics (Nasdaq: DMAC) reported a third-quarter net loss of $11.3 million while advancing its DM199 clinical programs. The loss widened from $8.6 million a year earlier. Cash, cash equivalents and short-term investments fell to $34.9 million at September 30, 2026, from $59.9 million at year-end 2025; the company expects funding to last into Q4 2027.

The first two Phase 2 early-onset fetal growth restriction cohorts completed enrollment with 12 participants; preliminary results are scheduled for November 24. ReMEDy2, the Phase 2/3 acute ischemic stroke trial, reached its 200-participant interim-analysis threshold, with analysis expected in Q1 2027. Health Canada authorized the Phase 2 early-onset preeclampsia study, while European authorization remains conditional. U.S. development requires additional reproductive-toxicity data review. Quarterly research and development expenses rose to $9.2 million from $6.4 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-5.79%
Tags
-
Rhea-AI Summary

DiaMedica Therapeutics (Nasdaq: DMAC) will release its third-quarter 2026 financial results after markets close on November 12, 2026. The company will host a live conference call on November 13, 2026, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss the results and provide a business update. A simultaneous webcast will be available, with playback accessible on the company’s website for 12 months after the call.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-16.06%
Tags
earnings date
-
Rhea-AI Summary

DiaMedica Therapeutics (DMAC) enrolled the 200th patient in its Phase 2/3 ReMEDy2 acute ischemic stroke trial, reaching its interim-analysis threshold.

An independent Data Safety Monitoring Board will review the data after the first 200 participants complete their 90-day follow-up. It will assess whether to adjust enrollment to preserve statistical power or stop for futility, meaning insufficient prospect of demonstrating benefit. If continued, final enrollment will range from 300 to 728 participants. DiaMedica expects completion of the analysis in Q1 2027; recruitment will continue during follow-up and review, and the company will remain blinded to the data.

The randomized, double-blind trial compares DM199 with placebo. Its primary efficacy endpoint is the proportion achieving a modified Rankin Score of 0 or 1 at Day 90, representing an excellent outcome. Treatment begins within 24 hours of symptom onset and lasts three weeks.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.69%
Tags
Rhea-AI Summary

DiaMedica Therapeutics (DMAC) rescheduled its DM199 fetal growth restriction webinar from October 23 to November 24, 2026, at 8:00 a.m. Eastern Time. The company said the later date will allow the presentation to include preliminary, interim topline results from the second cohort of its investigator-sponsored Phase 2 early-onset fetal growth restriction trial, alongside first-cohort results.

The panel will discuss interim safety and clinical findings from the first six participants treated. Principal investigator Catherine Cluver will present safety, tolerability and preliminary results, followed by a live question-and-answer session. The open-label, single-center, single-arm study is evaluating repeated injections under the skin in up to 30 participants until delivery. Enrollment began in June 2026. No trial results were disclosed in this update.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.96%
Tags
none
-
Rhea-AI Summary

DiaMedica Therapeutics (Nasdaq: DMAC) will host an October 23, 2026 webinar presenting preliminary Phase 2 findings for DM199 in early-onset fetal growth restriction. The virtual event begins at 8:00 AM EDT and will cover interim safety, tolerability and clinical findings from the first six treated participants. Principal investigator Catherine Cluver will present the results, followed by an expert panel discussion and live questions.

First-cohort enrollment is complete at 5 µg/kg, and dosing has begun in the second cohort at 10 µg/kg. The investigator-sponsored study at Tygerberg Hospital in Cape Town is open-label, single-center and single-arm, meaning it has no comparison group. It evaluates repeated injections under the skin until delivery in up to 30 participants with early-onset fetal growth restriction, across up to three dose levels.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.85%
Tags
-
Rhea-AI Summary

DiaMedica Therapeutics (DMAC) will participate in four investment bank healthcare conferences in New York in September 2026.

Management will attend the Citi Biopharma Back to School Summit on September 9–10, the Cantor Global Healthcare Conference on September 9–11 (including a fireside chat on September 11 at 10:20 a.m. ET), the Lake Street 10th Annual BIG10 Conference on September 10, and the HC Wainwright 28th Annual Global Investment Conference on September 14–16, featuring a company presentation on September 15 at 1:30 p.m. ET.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.65%
Tags
none
Rhea-AI Summary

DiaMedica Therapeutics (Nasdaq: DMAC) reported second quarter 2026 results and key clinical progress for lead candidate DM199 in preeclampsia, fetal growth restriction (FGR) and acute ischemic stroke (AIS). Cash, cash equivalents and short‑term investments were $43.5 million at June 30, 2026, which the company expects will fund operations through 2027.

In late‑onset preeclampsia Phase 2 Part 1a, DM199 produced statistically significant, sustained blood pressure reductions, including a mean 29.1 mmHg systolic and 17.0 mmHg diastolic decrease at five minutes post‑infusion in the highest‑dose cohorts (n=15). Enrollment of the first six‑patient cohort in the early‑onset FGR Phase 2 study is complete, and a KOL call with topline data is planned for September.

For AIS, the ReMEDy2 Phase 2/3 trial has surpassed 85% of the 200 participants needed for a prespecified interim analysis, expected in early 2027. R&D expenses rose to $8.2 million in Q2 2026, contributing to a quarterly net loss of $10.1 million.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.31%
Tags
-
Rhea-AI Summary

DiaMedica Therapeutics (Nasdaq: DMAC) plans to release its second quarter 2026 financial results after market close on Monday, August 10, 2026. The company will host a live conference call and webcast on Tuesday, August 11, 2026 at 8:00 AM EDT / 7:00 AM CDT to discuss the results and provide a business update.

Investors can access the call via dial-in at (646) 357-8766 using Conference ID 2224408, or through a webcast at https://app.webinar.net/d01wEPk9peA. A webcast replay will be available on DiaMedica’s website for 12 months, and a telephonic replay will be accessible until August 18, 2026 at (800) 770-2030 with passcode 2224408#.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.91%
Tags
earnings date
-
Rhea-AI Summary

DiaMedica Therapeutics (Nasdaq: DMAC) granted stock options to purchase an aggregate of 160,000 common shares on July 15, 2026 to a newly hired non-executive employee as a material inducement to employment under Nasdaq Listing Rule 5635(c)(4).

According to DiaMedica, the options were issued under its Amended and Restated 2021 Employment Inducement Incentive Plan, have a $7.64 exercise price (the July 15, 2026 closing price), a 10-year term, and vest 25% after one year with the remaining 75% vesting in 12 quarterly installments, subject to continued service.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-3.97%
Tags
none
Rhea-AI Summary

DiaMedica Therapeutics (Nasdaq: DMAC) reported dosing the first two patients in an investigator-sponsored Phase 2 trial of DM199 for early-onset fetal growth restriction (FGR). The open-label, single-arm study will assess three dose levels in up to 30 patients. DM199 aims to improve maternal uterine blood flow without crossing into fetal circulation. DiaMedica also released a white paper reviewing the scientific basis for DM199 in FGR.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.62%
Tags

FAQ

What is the current stock price of DiaMedica Therapeutics (DMAC)?

DiaMedica Therapeutics (DMAC) last closed at $8.33.

What is the market cap of DiaMedica Therapeutics (DMAC)?

The market cap of DiaMedica Therapeutics (DMAC) is approximately $449.5M.